Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
about
Optimizing sedation in patients with acute brain injurySedation in Critically Ill Children with Respiratory FailureLiterature mining on pharmacokinetics numerical data: a feasibility studyA semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.Effect of hepatic function on the EC50 of midazolam and the BIS50 at the time of loss of consciousness.Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis.Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteersPharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation.Preoperative evaluation of patients with liver disease.The pharmacologic management of insomnia in patients with HIV.Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.The Promises of Quantitative Proteomics in Precision MedicinePharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination.Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.Mycoplasma gallisepticum and Escherichia coli mixed infection model in broiler chickens for studying valnemulin pharmacokinetics.Case series of buprenorphine injectors in Kuala Lumpur, Malaysia.A maturation model for midazolam clearance.
P2860
Q26752789-37ADE4AE-1E2E-4E44-870C-EC0007B52E42Q28080112-C62E0932-0725-468B-8D7D-6BE51C2ABBAFQ33426634-EC02BA3C-73FF-4B81-93BF-009730B80EE2Q33532744-5D9B1991-D116-4DAC-9EFB-C940347B8C4EQ33721358-8715B39C-6118-4F13-BAD0-F5AC8C3C2A40Q34029472-05F0976B-068C-445C-B427-AD2E2C86FDE8Q34659732-5AE59BBA-4483-4E95-9A45-8DAFF0F287B0Q34720211-401CD38E-ED94-4874-AB7D-EDDAD93F07A1Q34819051-FB412554-CFD4-42CD-AACC-FD6F99C86311Q35803666-4242CACE-2856-4233-AA7C-A1C233A7F914Q36574931-0BBB0FA7-23FB-4F7C-8D2E-7CCF8044CE6BQ36809737-C923AB1F-0681-45A9-8AC8-9F2CF1BE3918Q37234441-86855227-0862-4E10-8BDB-AC44A972FFA8Q37317619-37E8B6A8-DE80-47D8-8170-310A25BF7A2FQ37492051-BE3007A7-E990-420B-AF3A-C0DD8BA87139Q37520997-034366EF-56E2-4D57-929F-99532A7E424CQ37647264-326E706F-FA5B-41BC-9C5F-E47539D2C444Q38152329-98A17526-54A8-41E7-8CBF-6310B90F5C9DQ39149746-E86E8951-33B1-4151-BFC7-F0AE1AE15C6AQ39810406-FCBEFF9E-C26F-4CF4-848A-17E9D686602FQ41328717-5F77D10B-6FDC-4C79-AB7A-501DC98E281BQ42282507-4584DB3B-E021-4332-8D56-5BB9A0A1D5A5Q43836988-32B921BC-E741-4242-B956-C6050E71A8FEQ44630465-DBD839FE-3883-48B5-8D9C-882C14CBD264Q46515339-E4567A74-8575-4C44-8999-F8A9EDC62B08Q48335810-327091FB-AC06-42C2-ADFB-0A93BBB981E7
P2860
Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@en
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@nl
type
label
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@en
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@nl
prefLabel
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@en
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@nl
P2093
P2860
P1476
Pharmacokinetics of midazolam ...... sease and in healthy subjects.
@en
P2093
Crevoisier C
Himberg JJ
Pentikäinen PJ
Välisalmi L
P2860
P304
P356
10.1002/J.1552-4604.1989.TB03327.X
P577
1989-03-01T00:00:00Z